Pulmonary Hypertension in Infants, Children, and Young Adults
Pulmonary hypertension (PH) in neonates, infants, children, adolescents, and young adults is a complex condition that can be associated with several cardiac, pulmonary, and systemic diseases contributing to morbidity and mortality. The underlying pulmonary hypertensive vascular disease (PHVD) is characterized by inflammation, pulmonary vascular remodeling, and angio-obliteration leading to elevated pulmonary arterial pressure and resistance, right ventricular dysfunction, left ventricular compression, and subsequent heart failure. Recent advancements in PH-targeted therapies and interventional-surgical procedures have contributed to the improvement in quality of life and survival in PH/PHVD. This paper gives an update on recent developments in the diagnosis and treatment of children and young adults with PH. The focus is on the heterogeneous etiology/pathophysiology of PH in the young, and particularly on PHVD associated with congenital heart disease. Moreover, new pharmacological, surgical, and interventional therapies and their practical application in progressive/severe pulmonary arterial hypertension with inadequate response to conventional pharmacotherapy are discussed..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:69 |
|---|---|
| Enthalten in: |
Journal of the American College of Cardiology - 69(2017), 20, Seite 2551-2569 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Hansmann, Georg [VerfasserIn] |
|---|
| Links: |
|---|
| RVK: |
|---|
| doi: |
10.1016/j.jacc.2017.03.575 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC1994890002 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1994890002 | ||
| 003 | DE-627 | ||
| 005 | 20230715055454.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jacc.2017.03.575 |2 doi | |
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1994890002 | ||
| 035 | |a (DE-599)GBVOLC1994890002 | ||
| 035 | |a (PRQ)e1882-270ad1e4ee56da68c469d8336571c0f4a7497961a05ed5e486873a2064acc5f10 | ||
| 035 | |a (KEY)0120600120170000069002002551pulmonaryhypertensionininfantschildrenandyoungadul | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 084 | |a XA 17760 |q AVZ |2 rvk | ||
| 100 | 1 | |a Hansmann, Georg |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pulmonary Hypertension in Infants, Children, and Young Adults |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Pulmonary hypertension (PH) in neonates, infants, children, adolescents, and young adults is a complex condition that can be associated with several cardiac, pulmonary, and systemic diseases contributing to morbidity and mortality. The underlying pulmonary hypertensive vascular disease (PHVD) is characterized by inflammation, pulmonary vascular remodeling, and angio-obliteration leading to elevated pulmonary arterial pressure and resistance, right ventricular dysfunction, left ventricular compression, and subsequent heart failure. Recent advancements in PH-targeted therapies and interventional-surgical procedures have contributed to the improvement in quality of life and survival in PH/PHVD. This paper gives an update on recent developments in the diagnosis and treatment of children and young adults with PH. The focus is on the heterogeneous etiology/pathophysiology of PH in the young, and particularly on PHVD associated with congenital heart disease. Moreover, new pharmacological, surgical, and interventional therapies and their practical application in progressive/severe pulmonary arterial hypertension with inadequate response to conventional pharmacotherapy are discussed. | ||
| 540 | |a Nutzungsrecht: © American College of Cardiology Foundation | ||
| 650 | 4 | |a Sea level | |
| 650 | 4 | |a Viruses | |
| 650 | 4 | |a Calcium channels (voltage-gated) | |
| 650 | 4 | |a Adults | |
| 650 | 4 | |a Cardiology | |
| 650 | 4 | |a Anatomy | |
| 650 | 4 | |a Ventricle | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Classification | |
| 650 | 4 | |a Failure | |
| 650 | 4 | |a Heart diseases | |
| 650 | 4 | |a Oxygen consumption | |
| 650 | 4 | |a Heart | |
| 650 | 4 | |a Surface area | |
| 650 | 4 | |a Lung diseases | |
| 650 | 4 | |a Circulation | |
| 650 | 4 | |a Wood | |
| 650 | 4 | |a Babies | |
| 650 | 4 | |a Schistosomiasis | |
| 650 | 4 | |a Epidemiology | |
| 650 | 4 | |a Mercury | |
| 650 | 4 | |a Young adults | |
| 650 | 4 | |a Developing countries | |
| 650 | 4 | |a Asphyxia | |
| 650 | 4 | |a Abnormalities | |
| 650 | 4 | |a Metabolism | |
| 650 | 4 | |a Infants | |
| 650 | 4 | |a Hypertension | |
| 650 | 4 | |a Age | |
| 650 | 4 | |a PH effects | |
| 650 | 4 | |a Arteries | |
| 650 | 4 | |a Medical services | |
| 650 | 4 | |a Angiogenesis | |
| 650 | 4 | |a Hemodynamics | |
| 650 | 4 | |a Survival | |
| 650 | 4 | |a Capillary pressure | |
| 650 | 4 | |a Bone morphogenetic protein receptor type II | |
| 650 | 4 | |a Genetics | |
| 650 | 4 | |a Risk factors | |
| 650 | 4 | |a Chorioamnionitis | |
| 650 | 4 | |a Lymphatic system | |
| 650 | 4 | |a Adolescents | |
| 650 | 4 | |a Mortality | |
| 650 | 4 | |a Etiology | |
| 650 | 4 | |a Transplantation | |
| 650 | 4 | |a Mutations | |
| 650 | 4 | |a Adolescence | |
| 650 | 4 | |a Wedges | |
| 650 | 4 | |a Pulmonary hypertension | |
| 650 | 4 | |a Children | |
| 650 | 4 | |a Alveoli | |
| 650 | 4 | |a Fetuses | |
| 650 | 4 | |a Hypoplasia | |
| 650 | 4 | |a Health risks | |
| 650 | 4 | |a Risk | |
| 650 | 4 | |a Catheterization | |
| 650 | 4 | |a Health care | |
| 650 | 4 | |a Lung | |
| 650 | 4 | |a Anomalies | |
| 650 | 4 | |a Pulmonary arteries | |
| 650 | 4 | |a Neonates | |
| 650 | 4 | |a Children & youth | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of the American College of Cardiology |d New York, NY : Elsevier, 1983 |g 69(2017), 20, Seite 2551-2569 |w (DE-627)130402028 |w (DE-600)605507-2 |w (DE-576)015904458 |x 0735-1097 |7 nnns |
| 773 | 1 | 8 | |g volume:69 |g year:2017 |g number:20 |g pages:2551-2569 |
| 856 | 4 | 1 | |u http://dx.doi.org/10.1016/j.jacc.2017.03.575 |3 Volltext |
| 856 | 4 | 2 | |u http://www.sciencedirect.com/science/article/pii/S073510971736850X |
| 856 | 4 | 2 | |u https://search.proquest.com/docview/1901359210 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2414 | ||
| 912 | |a GBV_ILN_4219 | ||
| 936 | r | v | |a XA 17760 |
| 951 | |a AR | ||
| 952 | |d 69 |j 2017 |e 20 |h 2551-2569 | ||